Rekombinanter PCSK9 Antikörper
-
- Target Alle PCSK9 Antikörper anzeigen
- PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))
- Antikörpertyp
- Recombinant Antibody
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser PCSK9 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
- Kreuzreaktivität
- Human
- Aufreinigung
- Affinity-chromatography
- Immunogen
- A synthesized peptide derived from human PCSK9
- Klon
- 7F2
- Isotyp
- IgG
- Top Product
- Discover our top product PCSK9 Primärantikörper
-
-
- Applikationshinweise
- Recommended dilution: WB:1:500-1:5000, IHC:1:50-1:200,
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Target
- PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))
- Andere Bezeichnung
- PCSK9 (PCSK9 Produkte)
- Synonyme
- FH3 antikoerper, HCHOLA3 antikoerper, LDLCQ1 antikoerper, NARC-1 antikoerper, NARC1 antikoerper, PC9 antikoerper, AI415265 antikoerper, AI747682 antikoerper, Narc1 antikoerper, proprotein convertase subtilisin/kexin type 9 antikoerper, proprotein convertase subtilisin/kexin type 9 L homeolog antikoerper, PCSK9 antikoerper, pcsk9.L antikoerper, pcsk9 antikoerper, Pcsk9 antikoerper
- Hintergrund
-
Background: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Aliases: Proprotein convertase subtilisin/kexin type 9 (EC 3.4.21.-) (Neural apoptosis-regulated convertase 1) (NARC-1) (Proprotein convertase 9) (PC9) (Subtilisin/kexin-like protease PC9), PCSK9, NARC1
- UniProt
- Q8NBP7
-